About this event
Chat with HeartSciences’ CEO About Our Private Investment Opportunity.
Join us on May 14th for an exclusive Investor Q&A with HeartSciences' CEO, Andrew Simpson. We’ll deep-dive into how our AI-ECG technology enhances traditional frontline diagnostics—and why you shouldn’t miss out on this Reg A opportunity:
With IP licensing and equity investment from Mount Sinai, our tech aims to become the go-to solution for more accessible, effective frontline heart disease detection. Save your seat now and discover how you can invest in HeartSciences on better terms than Wall Street.
Disclaimer:
HeartSciences Inc. (“HeartSciences”) is offering securities through the use of an Offering Statement that has been qualified by the U.S. Securities and Exchange Commission (the “SEC”) under Tier II of Regulation A. Before making any investment, you are urged to read the final Offering Circular that forms a part of the Offering Statement that has been filed with the SEC carefully for a more complete understanding of HeartSciences and the offering. There is no guarantee of return, and you should only invest money that you can afford to lose. Use proper risk management when considering this investment.
The securities offered by HeartSciences are highly speculative. Investing in these securities involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Investors must understand that such investment could be illiquid for an indefinite period of time. There is no existing public trading market for the Series D Preferred Stock or the related common stock purchase warrants. HeartSciences does not intend to apply for listing of the Series D Preferred Stock or the common stock purchase warrants on a national securities exchange or to be quoted on an over-the-counter market. A copy of the final Offering Circular may be obtained from: Here
Hosted by
